Cargando…
Closed-loop bioelectronic medicine for diabetes management
Modulation of the nervous system by delivering electrical or pharmaceutical agents has contributed to the development of novel treatments to serious health disorders. Recent advances in multidisciplinary research has enabled the emergence of a new powerful therapeutic approach called bioelectronic m...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227365/ https://www.ncbi.nlm.nih.gov/pubmed/32467827 http://dx.doi.org/10.1186/s42234-020-00046-4 |
_version_ | 1783534489229590528 |
---|---|
author | Güemes Gonzalez, Amparo Etienne-Cummings, Ralph Georgiou, Pantelis |
author_facet | Güemes Gonzalez, Amparo Etienne-Cummings, Ralph Georgiou, Pantelis |
author_sort | Güemes Gonzalez, Amparo |
collection | PubMed |
description | Modulation of the nervous system by delivering electrical or pharmaceutical agents has contributed to the development of novel treatments to serious health disorders. Recent advances in multidisciplinary research has enabled the emergence of a new powerful therapeutic approach called bioelectronic medicine. Bioelectronic medicine exploits the fact that every organ in our bodies is neurally innervated and thus electrical interfacing with peripheral nerves can be a potential pathway for diagnosing or treating diseases such as diabetes. In this context, a plethora of studies have confirmed the important role of the nervous system in maintaining a tight regulation of glucose homeostasis. This has initiated new research exploring the opportunities of bioelectronic medicine for improving glucose control in people with diabetes, including regulation of gastric emptying, insulin sensitivity, and secretion of pancreatic hormones. Moreover, the development of novel closed-loop strategies aims to provide effective, specific and safe interfacing with the nervous system, and thereby targeting the organ of interest. This is especially valuable in the context of chronic diseases such as diabetes, where closed-loop bioelectronic medicine promises to provide real-time, autonomous and patient-specific therapies. In this article, we present an overview of the state-of-the-art for closed-loop neuromodulation systems in relation to diabetes and discuss future related opportunities for management of this chronic disease. |
format | Online Article Text |
id | pubmed-7227365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72273652020-05-27 Closed-loop bioelectronic medicine for diabetes management Güemes Gonzalez, Amparo Etienne-Cummings, Ralph Georgiou, Pantelis Bioelectron Med Mini-Review Modulation of the nervous system by delivering electrical or pharmaceutical agents has contributed to the development of novel treatments to serious health disorders. Recent advances in multidisciplinary research has enabled the emergence of a new powerful therapeutic approach called bioelectronic medicine. Bioelectronic medicine exploits the fact that every organ in our bodies is neurally innervated and thus electrical interfacing with peripheral nerves can be a potential pathway for diagnosing or treating diseases such as diabetes. In this context, a plethora of studies have confirmed the important role of the nervous system in maintaining a tight regulation of glucose homeostasis. This has initiated new research exploring the opportunities of bioelectronic medicine for improving glucose control in people with diabetes, including regulation of gastric emptying, insulin sensitivity, and secretion of pancreatic hormones. Moreover, the development of novel closed-loop strategies aims to provide effective, specific and safe interfacing with the nervous system, and thereby targeting the organ of interest. This is especially valuable in the context of chronic diseases such as diabetes, where closed-loop bioelectronic medicine promises to provide real-time, autonomous and patient-specific therapies. In this article, we present an overview of the state-of-the-art for closed-loop neuromodulation systems in relation to diabetes and discuss future related opportunities for management of this chronic disease. BioMed Central 2020-05-15 /pmc/articles/PMC7227365/ /pubmed/32467827 http://dx.doi.org/10.1186/s42234-020-00046-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Mini-Review Güemes Gonzalez, Amparo Etienne-Cummings, Ralph Georgiou, Pantelis Closed-loop bioelectronic medicine for diabetes management |
title | Closed-loop bioelectronic medicine for diabetes management |
title_full | Closed-loop bioelectronic medicine for diabetes management |
title_fullStr | Closed-loop bioelectronic medicine for diabetes management |
title_full_unstemmed | Closed-loop bioelectronic medicine for diabetes management |
title_short | Closed-loop bioelectronic medicine for diabetes management |
title_sort | closed-loop bioelectronic medicine for diabetes management |
topic | Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227365/ https://www.ncbi.nlm.nih.gov/pubmed/32467827 http://dx.doi.org/10.1186/s42234-020-00046-4 |
work_keys_str_mv | AT guemesgonzalezamparo closedloopbioelectronicmedicinefordiabetesmanagement AT etiennecummingsralph closedloopbioelectronicmedicinefordiabetesmanagement AT georgioupantelis closedloopbioelectronicmedicinefordiabetesmanagement |